GHK-Cu

• Research applications include copper–peptide coordination and stoichiometry, analytical identity and impurity methods, fibroblast and extracellular-matrix models, wound-model research, formulation stability and properly substantiated cosmetic-ingredient evaluation
• Cosmetic or preclinical observations are not proof of injectable, wound-healing, hair-growth or anti-ageing efficacy.

CAS

89030-95-5

Formula

C₁₄H₂₂CuN₆O₄

Molecular weight

401.91 g/mol

Appearance

Lot-specific lyophilized solid; confirm colour, physical form and copper basis on the released-lot COA

Purity

Lot-specific released result; require chromatography, quantitative peptide content or assay, copper content and orthogonal identity · target, verify batch COA

Storage

Follow the released-lot COA, SDS and lot-specific stability statement. Copper complexation, salt form, excipients, concentration, matrix, container and light exposure can change stability; do not copy a finished cosmetic shelf life or generic post-reconstitution period to this lot.

MOQ

1 kit (10 vials) per SKU

Lead time

Confirmed with quote

GHK-Cu is a copper(II) complex of the Gly-His-Lys tripeptide. Reviews describe extensive cell and animal work on extracellular-matrix, wound and gene-expression models, while human evidence is concentrated in specific topical formulations and is more limited than marketing summaries imply. PubChem CID 378611 is a neutral Cu-GHK representation and CID 71587328 is a cationic prezatide-copper representation; free GHK CID 73587 and acetate-associated CID 154723978 are different records. Copper Tripeptide-1 is an INCI ingredient name, not FDA approval. FDA states that compounded injectable GHK-Cu may pose immunogenicity risk from aggregation and peptide-related impurities and that human safety data are limited.

• Copper-complex identity and stoichiometry; analytical and stability method development; controlled fibroblast, extracellular-matrix, wound, inflammatory and angiogenesis models; and cosmetic-formulation research with substantiated claims
• These are research applications, not clinical indications.

GHK coordinates copper(II) through donor atoms in the tripeptide and is studied as a copper-delivery and signalling complex. Cell and animal models report changes in fibroblast activity, extracellular-matrix synthesis and remodelling, metalloproteinase balance, inflammatory signalling and angiogenesis-related endpoints. Results depend on chemical form, copper stoichiometry, model, formulation, concentration and delivery context and do not establish clinical efficacy or injectable safety.

• Not for injection or other human or veterinary administration
• FDA states that compounded injectable GHK-Cu may pose immunogenicity risk because of potential aggregation and peptide-related impurities and that human data are limited for safety assessment
• For cosmetic R&D, the CIR conclusion applies only to the cosmetic practices and concentrations assessed; ingredient-level information does not establish finished-product safety
• Irritation, sensitisation, microbiological quality, stability, exposure and claims require formulation-specific assessment under applicable law
• Follow the SDS and institutional controls.

Interactions reported in the literature

• No general compatibility or drug-interaction guidance applies
• Stability and compatibility with acids, reducing agents, chelators, oxidants, other peptides, preservatives or packaging must be tested in the exact formulation; vendor pairings with BPC-157, TB-500 or CJC-1295 are not evidence.

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

• 50 mg
• 100 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

• Require exact peptide and copper-complex identity, charge/salt convention, theoretical and observed intact mass, orthogonal peptide identity, quantitative peptide content, copper assay and stoichiometry, stability-indicating HPLC purity and impurity profile, water/counterion/residual solvents and lot-specific stability
• Microbial limits, preservative effectiveness and finished-product compatibility are separate tests
• Colour or clarity alone is not a release test.

Follow the released-lot COA, SDS and lot-specific stability statement. Copper complexation, salt form, excipients, concentration, matrix, container and light exposure can change stability; do not copy a finished cosmetic shelf life or generic post-reconstitution period to this lot.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

• Identity: NIH PubChem CIDs 378611, 71587328, 73587 and 154723978, which distinguish neutral Cu-GHK, cationic prezatide copper, free GHK and an acetate-associated record. Scientific context: PMID 29986520 / PMCID PMC6073405, PMCID PMC4508379, PMCID PMC4180391 and the foundational 1980 Nature copper-uptake paper. Cosmetic context: CIR's final Tripeptide-1 safety assessment, limited to the practices and concentrations reviewed. Regulatory context: current FDA cosmetics guidance and FDA's injectable-GHK-Cu entry among withdrawn bulk-substance nominations that may present significant safety risks. Each study and order must retain its exact chemical form and formulation.

1. 01

   Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver

   Nature New Biology · 1973 · peer-reviewed original research (landmark discovery paper)

   Open source
2. 02

   Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+

   FEBS Letters · 1988 · peer-reviewed original research (landmark mechanism paper)

   Open source
3. 03

   The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health

   Oxidative Medicine and Cellular Longevity · 2012 · peer-reviewed review article

   Open source
4. 04

   Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

   International Journal of Molecular Sciences · 2018 · peer-reviewed review article

   Open source
5. 05

   The potential of GHK as an anti-aging peptide

   Aging Pathobiology and Therapeutics · 2020 · peer-reviewed review article

   Open source
6. 06

   Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters

   Journal of Aging Science · 2016 · original report (in vitro work plus a small topical comparison; journal quality and independent replication limitations apply)

   Open source
7. 07

   Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics

   International Journal of Toxicology (published on behalf of the Cosmetic Ingredient Review Expert Panel) · 2018 · Cosmetic Ingredient Review expert-panel safety assessment (cosmetic-use context; not FDA approval)

   Open source
8. 08

   Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial

   EurekAlert! (AAAS-operated science news release platform); Yuvan Research Inc. · 2023 · company press release / clinical study announcement

   Open source

• How to read a peptide COA without confusing purity, identity and content
• Peptide purity versus peptide content: a buyer’s method map
• Questions to ask a research peptide supplier before the first purchase order